Herschorn, S., Nazir, J., Ramos, B. and Hakimi, Z. 2017. Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal. 11, 3-4 (Apr. 2017), 123–30. DOI:https://doi.org/10.5489/cuaj.4114.